Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launchToronto, Ontario and Chicago, ...

Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, has a portfolio of products aimed at ...

Virginia’s proposed prescription drug affordability board would positioning the government as an arbiter of medical value and access, the Rare Access Action Project’s Michael Eging ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Read the full report on the stock here.

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...

House Study Bill 15 criminalizes the act of smuggling noncitizens for pay or other benefits. Smuggling actions would include ...

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX), a biotechnology company focused on fibrotic diseases with a market capitalization of $674 million, has named Delphine Imbert, Ph.D., as ...

Drug testing may be required as a prerequisite for some jobs. State laws may dictate when private employers can require drug tests and how they can use the results. Job candidates for “safety ...